Harrow (HROW) Capital Expenditures Growth (3y) (2015 - 2026)
Harrow (HROW) Capital Expenditures Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | 25.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.23% |
| Mar 31, 2026 | -26.87% |
| Dec 31, 2025 | -27.04% |
| Sep 30, 2025 | -26.67% |
| Jun 30, 2025 | -29.14% |
| Mar 31, 2025 | -25.06% |
| Dec 31, 2024 | 117.93% |
| Sep 30, 2024 | -22.79% |
| Jun 30, 2024 | -26.81% |
| Mar 31, 2024 | -25.00% |
| Dec 31, 2023 | 33.25% |
| Sep 30, 2023 | 67.71% |
| Jun 30, 2023 | -47.45% |
| Mar 31, 2023 | 31.13% |
| Dec 31, 2022 | -0.04% |
| Sep 30, 2022 | 252.92% |
| Jun 30, 2022 | -9.61% |
| Mar 31, 2022 | 23.78% |
| Dec 31, 2021 | -41.94% |
| Sep 30, 2021 | -17.68% |